- Home
- MLAB vs ALT Comparison
MLAB vs ALT Comparison
Compare MLAB & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLAB | ALT |
|---|---|---|
| Founded | 1982 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.4M | 415.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MLAB | ALT |
|---|---|---|
| Price | $89.26 | $4.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $83.00 | $16.33 |
| AVG Volume (30 Days) | 102.8K | ★ 5.9M |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,255,000.00 | $20,000.00 |
| Revenue This Year | $4.96 | N/A |
| Revenue Next Year | $5.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.39 | N/A |
| 52 Week Low | $55.45 | $2.90 |
| 52 Week High | $155.12 | $7.73 |
Technical Indicators
Market Signals| Indicator | MLAB | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 65.53 | 50.65 |
| Support Level | $80.00 | $3.96 |
| Resistance Level | $89.95 | $4.40 |
| Average True Range (ATR) | 4.23 | 0.24 |
| MACD | 0.40 | 0.06 |
| Stochastic Oscillator | 88.59 | 74.48 |
Price Performance
Historical ComparisonAbout MLAB Mesa Laboratories Inc.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.